ANTARES PHARMA, INC.

Form 4/A March 12, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB

Expires:

3235-0287 Number: January 31,

OMB APPROVAL

2005 Estimated average

burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

Stock

1(b).

(Print or Type Responses)

1. Name and A APPLE RO	2. Issuer Name and Ticker or Trading Symbol						5. Relationship of Reporting Person(s) to Issuer					
(Last) (First) (Middle)			ANTARES PHARMA, INC. [ATRS]					IIIOJ	(Check all applicable)			
(Last) C/O ANTAI INC., 100 P SUITE 300	3. Date of Earliest Transaction (Month/Day/Year) 05/21/2014						Director 10% Owner X Officer (give title Other (specify below) below) Executive Vice President & COO					
	(Street)	4. If Amendment, Date Original						6. Individual or Joint/Group Filing(Check				
	Filed(Month/Day/Year)						Applicable Line) _X_ Form filed by One Reporting Person					
EWING, NJ	02/12/2015						Form filed by More than One Reporting Person					
(City)	(State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transact Code (Instr. 8)	ioi	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Amount (D) Price			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) Form: 7. Nature o Indirect Beneficial Ownership (Instr. 4)	Indirect Beneficial Ownership	
Common Stock	05/21/2014			F		3,526 (1)	D	\$ 2.97	340,392	D		
Common Stock	02/10/2015			A		12,519 (2)	A	\$0	360,234 (3)	D		
Common Stock	02/10/2015			F		4,779	D	\$ 2.36	355,455 <u>(3)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form

2.36

SEC 1474 (9-02)

Edgar Filing: ANTARES PHARMA, INC. - Form 4/A

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	isable and	7. Titl	e and	8. Price of	9
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orNumber	Expiration Da	ate	Amou	nt of	Derivative	J
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	lying	Security	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Secur	ities	(Instr. 5)]
	Derivative				Securities			(Instr.	3 and 4)		(
Security					Acquired						J
					(A) or						J
					Disposed						7
					of (D)						(
					(Instr. 3,						
					4, and 5)						
									A 4		
									Amount		
						Date	Expiration	T:41-	or Namelana		
						Exercisable	Date		Number		
				C 1 W	(A) (D)				of		
				Code V	(A) (D)				Shares		

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

03/12/2015

APPLE ROBERT F C/O ANTARES PHARMA, INC. 100 PRINCETON SOUTH, SUITE 300 EWING, NJ 08628

Executive Vice President & COO

Signatures

Jennifer Evans Stacey as attorney-in-fact for Robert F. Apple

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These shares withheld for tax purposes were not timely reported.
 - On July 6, 2012, Mr. Apple received a performance stock unit award under the 2008 Equity Compensation Plan. The target number of shares under the award is 25,039 shares, and the award is contingent upon the Company's achieving certain performance goals over the
- three-year period beginning January 1, 2012 and ending December 31, 2014. The 12,519 shares reported here represent the number of shares vested on February 10, 2015 upon the Company's achievement of a performance goal. 12,520 shares of the award remain subject to performance goals and may be earned by Mr. Apple pursuant to the terms of the award. Until earned, they have been removed from the amount of securities beneficially owned.
- (3) Includes 32,362 shares of restricted common stock granted to Mr. Apple on 05/29/2014 and reported on a Form 4 dated 06/02/2014. The original Form 4 filed on 02/12/2015 did not include these 32,362 shares of restricted common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2

of 9. Nuve Deriv Secur Bene Own Follo Repo

Repo Trans (Instr